Treatment (Visits Sample Clauses

Treatment (Visits. Subjects that did not experience significant pain or skin sensitivity in response to the test spots can receive treatments. Each subject will be enrolled and scheduled for two treatments, three weeks apart and return for a follow-up visit three days after the second treatment for evaluation of the treatment area. The following procedures and assessments are required at the treatment visits:  Confirm continued eligibility regarding inclusion/exclusion criteria  Review any changes in medication, health status or AE from last visit  Assessment of adverse events including a photograph of the affected treatment area if an adverse event occurred  Assessment of concomitant medications  Assign randomized treatment (after 1st treatment visit only)  Apply a topical anesthetic preparation over the treatment areas, if required. (If used, record in the CRF.) No lotion, gel or coupling medium is to be used in this treatment. The distal part of the applicator should be clean and dry before fitting it with a new 160 pins tip. The skin in the treated area should also be cleaned well (for removal of any lotions, make-up residues, topical anesthetic cream, etc.) and patted dry. Hairs that exist in the areas should be shaved off.  Treatment should be performed while the subject is lying down comfortably; the operator should have easy access to the subject’s treatment area.  Areas of dental crowns, caps, braces, or other metal dental implants may be more sensitive to treatment and the clinician may use dental rolls, gauze or a tongue depressor to isolate the area and make the treatment more comfortable (if the face is treated).  Treatment of subjects in hair-bearing areas may result in some damage to the follicles and subsequent loss of hair. Avoid the ▇▇▇▇▇ area (if face is treated) and other hair growing zones if the patient doesn’t wish to have reduction of the hair growth. This treatment may also result in in- grown hairs.  The applicator should be held perpendicular to and in close contact with the skin.  Pressing the trigger will release the RF energy to the skin, creating a stamped imprint in a shape and intensity depending on energies.  The immediate responses, indicative of the desired effect, are erythema and edema in the immediate area of the stamp and possibly also around it. The edema usually appears 1-2 minutes post-treatment and reaches its peak (of up to moderate edema) within 30 minutes. It should be noted that erythema is not easily noticeable, if...
Treatment (Visits. 4 through 16) *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Related to Treatment (Visits

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Defendants, and Defendants shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Defendants or any of their subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • SPECIALIZED SERVICE REQUIREMENTS In the event that the Participating Entity requires service or specialized performance requirements not addressed in this Contract (such as e- commerce specifications, specialized delivery requirements, or other specifications and requirements), the Participating Entity and the Supplier may enter into a separate, standalone agreement, apart from this Contract. Sourcewell, including its agents and employees, will not be made a party to a claim for breach of such agreement.

  • Surgery Services and Mastectomy Related Treatment This plan provides benefits for mastectomy surgery and mastectomy-related services in accordance with the Women’s Health and Cancer Rights Act of 1998 and Rhode Island General Law 27-20-29 et seq. For the member receiving mastectomy-related benefits, coverage will be provided in a manner determined in consultation with the attending physician, physician assistant, or an advance practice registered nurse and the patient, for: • all stages of reconstruction of the breast on which the mastectomy was performed; • surgery and reconstruction of the other breast to produce a symmetrical appearance; • prostheses; and • treatment of physical complications at all stages of the mastectomy, including lymphedema. See the Summary of Medical Benefits for the amount you pay.

  • TREATMENT REQUESTED Buyer shall defend, indemnify and hold harmless Myriant from and against all loss, costs, expenses, damages and liability of any kind arising out of any claims of infringement or alleged infringement of any patent or other intellectual property right with respect to (i) the use of Products in any application by Buyer or its affiliates, contract manufacturers or customers, including but not limited to the use of Products alone or in combination with other substances or components; (ii) any modification to the Products by Buyer or its affiliates, contract manufacturers or customers; or (iii) Products furnished, or methods used, by Myriant in accordance with the specifications or instructions furnished by or expressly or implicitly prescribed by Buyer.